Circulating Microvesicles Enriched in miR–126–5p and miR–223–3p: Potential Biomarkers in Acute Coronary Syndrome
José Rubicel Hernández-López,
Mirthala Flores-García,
Esbeidy García-Flores,
Benny Giovanni Cazarín-Santos,
Marco Antonio Peña-Duque,
Fausto Sánchez-Muñoz,
Martha Alicia Ballinas-Verdugo,
Hilda Delgadillo-Rodríguez,
Marco Antonio Martínez-Ríos,
Eduardo Angles-Cano,
Aurora de la Peña-Díaz
Affiliations
José Rubicel Hernández-López
Pharmacology Department, Faculty of Medicine, National Autonomous University of Mexico, Circuito Escolar, Ciudad Universitaria, Coyoacán, Mexico City 04510, Mexico
Mirthala Flores-García
Molecular Biology Department, National Institute of Cardiology Ignacio Chávez, Juan Badiano 1, Tlalpan, Mexico City 14080, Mexico
Esbeidy García-Flores
Molecular Biology Department, National Institute of Cardiology Ignacio Chávez, Juan Badiano 1, Tlalpan, Mexico City 14080, Mexico
Benny Giovanni Cazarín-Santos
Pharmacology Department, Faculty of Medicine, National Autonomous University of Mexico, Circuito Escolar, Ciudad Universitaria, Coyoacán, Mexico City 04510, Mexico
Marco Antonio Peña-Duque
Cardiology Service, Medica Sur. Puente de Piedra 150, Toriello Guerra, Tlalpan, Mexico City 14050, Mexico
Fausto Sánchez-Muñoz
Physiology Department, National Institute of Cardiology Ignacio Chávez, Juan Badiano 1, Tlalpan, Mexico City 14080, Mexico
Martha Alicia Ballinas-Verdugo
Immunology Department, National Institute of Cardiology Ignacio Chávez, Juan Badiano 1, Tlalpan, Mexico City 14080, Mexico
Hilda Delgadillo-Rodríguez
Department of Hospitalization, National Institute of Cardiology Ignacio Chávez, Juan Badiano 1, Tlalpan, Mexico City 14080, Mexico
Marco Antonio Martínez-Ríos
Independent Researcher, Tlalpan, Mexico City 14050, Mexico
Eduardo Angles-Cano
INSERM UMR_S-1140 & UMR_S-1144, Innovation Diagnostique et Thérapeutique en Pathologies Cérébrovasculaires et Thrombotiques, Faculté de Pharmacie de Paris, Université Paris Cité, 75006 Paris, France
Aurora de la Peña-Díaz
Pharmacology Department, Faculty of Medicine, National Autonomous University of Mexico, Circuito Escolar, Ciudad Universitaria, Coyoacán, Mexico City 04510, Mexico
Background. The molecular mechanisms underlying acute coronary syndrome (ACS) have been extensively investigated, with a particular focus on the role of circulating microvesicles (MVs) as carriers of regulatory elements that influence hemodynamic changes and coronary flow. Endothelial and platelet dysfunction during ACS alters MV composition, impacting clinical outcomes. This study explores the levels of miR–126–5p and miR–223–3p in circulating MVs and their association with the Thrombolysis in Myocardial Infarction (TIMI) coronary flow classification scale, proposing their potential as biomarkers. Methods. Bioinformatic tools identified miRNAs linked to ACS. Plasma MVs were isolated from ACS patients and healthy controls through high-speed centrifugation. miRNA levels were quantified using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and compared across TIMI 0 and TIMI 3 groups. Diagnostic efficacy was assessed via receiver operating characteristic (ROC) curve analysis. Results. The bioinformatic analysis identified miR–126 and miR–223 present in ACS. miR–126–5p and miR–223–3p were significantly reduced in MVs from TIMI 0 patients compared to TIMI 3. ROC analysis showed high diagnostic accuracy for miR–126–5p (AUC = 0.918; 95% CI: 0.818–1.00; p = 0.001) and miR–223–3p (AUC = 1.00; 95% CI: 1.00–1.00; p Conclusions. Reduced levels of miR–126–5p and miR–223–3p in circulating MVs are strongly associated with impaired coronary flow, positioning these miRNAs as potential biomarkers for ACS risk stratification and therapeutic targeting.
